The global Scleroderma Treatment Market was valued at US$ 1.46 billion in 2021 and is predicted to grow at a 4.8% year-on-year rate to US$ 1.53 billion in FY 2022. Sales are predicted to grow at a CAGR of 5.45% between 2022 and 2032, reaching US$ 2.6 billion.
Scleroderma is an autoimmune illness that affects the blood vessels, skin, muscles, and other organs. When exposed to cold, scleroderma symptoms include thickened and tight skin, lethargy, and decreased blood flow to extremities of the limbs such as fingers and toes. Calcium deposits, Raynaud's syndrome, and esophageal difficulties can all be caused by scleroderma.
The key drivers of the Scleroderma market are the disease's rising incidence and screening rates. Scleroderma has a prevalence of 240 per million people in the United States, with an annual incidence of 19 per million, indicating a large unmet need. Scleroderma is predicted to affect 10 to 150 persons per million in Europe, with an annual incidence of 3 to 28 people per million.
The increased risk of exposure to risk factors such as silica, aromatic and chlorinated solvents, ketones, welding fumes, and the development of advanced high sensitive and selective skin biopsy and blood tests are driving market expansion.
Some of the major players in the global Scleroderma Treatment market are Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., Sanofi, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc. and Actelion Pharmaceuticals, Inc.
Know More About Report@ https://www.futuremarketinsights.com/reports/scleroderma-treatment-market
Scleroderma Treatment Market: Segmentation
The scleroderma treatment market is segmented on the basis of drug class, types, distribution channel and region.
Based on drug class, the global scleroderma treatment market is segmented into:
- Anti-inflammatory agents
- Immunosuppressive agents
- Vascular agents
- Anti-fibrotic agents
Based on types, the global scleroderma treatment market is segmented into:
Based on distribution channel, the global scleroderma treatment market is segmented into:
- Institutional Sales
- Retail Sales
- Online Sales